Digest Network Come funziona
Network
/
Società
CE
Non verificato

CEL-SCI Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

41 comunicati stampa

Guarda tutti i comunicati
29/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Finanza
CEL-SCI Announces Closing of $10 Million Public Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
28/08/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Finanza
CEL-SCI Announces Pricing of $10 Million Public Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
27/08/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Finanza
CEL-SCI Announces Proposed Public Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
14/08/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Mercato azionario
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
13/08/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Industria
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
14/07/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Sanità
Finanza
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
11/07/2025
Igiene alimentare
Salute
Oncologia
Medicina - Varie
Finanza
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
11/07/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
18/06/2025
Medicina - Varie
Igiene alimentare
Biotecnologia
Sanità
Medicina nucleare
Salute
Farmaceutica
Oncologia
Industria
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0
23/05/2025
Finanza
Oncologia
Salute
Medicina - Varie
Medicina nucleare
Farmaceutica
Biotecnologia
CEL-SCI Announces Closing of Public Offering
Fonte
CEL-SCI Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0